2020
Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy
Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo W, Richards D, Halperin D, Ge P, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clinical Colorectal Cancer 2020, 19: e117-e123. PMID: 32284253, DOI: 10.1016/j.clcc.2020.03.002.Peer-Reviewed Original ResearchConceptsAbnormal endoscopic findingsAntiangiogenesis cancer therapyIntensive care unitAntiangiogenesis therapyACD symptomsAntimotility agentsEndoscopic findingsColonic perforationCare unitTertiary care cancer centerActive histologic inflammationRare adverse eventsCancer therapyEnterocolitis symptomsHistologic inflammationNonulcerative inflammationUnderlying malignancyGastrointestinal injuryGastrointestinal toxicityMucosal ulcerationUnderwent endoscopyAdverse eventsMedian durationMost patientsEndoscopic evaluation
2019
Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier R, Richards D, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal Of Gastroenterology 2019, 54: 538-545. PMID: 31079556, DOI: 10.1080/00365521.2019.1594356.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUpper GI symptomsRisk factorsGI symptomsCheckpoint inhibitorsGI inflammationAnti-PD-1/L1Non-steroidal anti-inflammatory drugsUpper GI injuryUpper GI toxicityGastrointestinal adverse eventsUpper gastrointestinal symptomsProton pump inhibitorsLower GI tractAnti-inflammatory drugsRate of ulcerationGI injuryICI initiationDuodenal involvementEndoscopic evidenceGastrointestinal symptomsGI toxicityImmunosuppressive therapyAdverse eventsGastric involvementAcute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang H, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal For ImmunoTherapy Of Cancer 2019, 7: 47. PMID: 30777137, PMCID: PMC6380028, DOI: 10.1186/s40425-019-0532-1.Peer-Reviewed Original ResearchConceptsImmune-related adverse reactionsGrade 3 colitisGastrointestinal reactionsLiver injuryClinical historyImmune checkpoint inhibitor-related colitisBackgroundImmune checkpoint inhibitorsElevated liver enzymesPD-1 inhibitorsTNF-α agentsAcute liver injuryInflammatory bowel diseaseOne-time infusionInfliximab therapyAcute hepatitisCheckpoint inhibitorsRescue therapyAdvanced malignanciesBiologic agentsBowel diseaseLiver profileCase presentationWePatient populationCTLA-4Final diagnosisGastroesophageal junction Paneth cell carcinoma with extensive cystic and secretory features – case report and literature review
Luo W, Hofstetter W, Tan D. Gastroesophageal junction Paneth cell carcinoma with extensive cystic and secretory features – case report and literature review. Diagnostic Pathology 2019, 14: 1. PMID: 30621725, PMCID: PMC6323739, DOI: 10.1186/s13000-018-0775-z.Peer-Reviewed Original ResearchConceptsNeoplastic Paneth cellsGastroesophageal junctionCell carcinomaPaneth cellsImmunohistochemical stainsProton pump inhibitor therapySubsequent endoscopic mucosal resectionHER2/neu statusBeta-catenin pathwayUpper gastrointestinal bleedingDiagnosis of adenocarcinomaEndoscopic mucosal resectionHER2/neuPeculiar histologic featuresDistinct staining patternsGastrointestinal bleedingCase presentationAInhibitor therapyClinical courseMucosal resectionHistologic featuresBarrett's esophagusEmergency roomTypical adenocarcinomaSecretory changes
2018
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. Journal For ImmunoTherapy Of Cancer 2018, 6: 142. PMID: 30518410, PMCID: PMC6280383, DOI: 10.1186/s40425-018-0461-4.Peer-Reviewed Original ResearchConceptsMean durationImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisImmune checkpoint inhibitor treatmentAbnormal endoscopic findingsActive histologic inflammationCheckpoint inhibitor treatmentClinical success rateRetrospective case seriesGood safety profileFeatures of chronicityMulti-center studyEndoscopic remissionHistologic inflammationHistologic remissionICI therapyNonulcerative inflammationSteroid therapyVedolizumab infusionsVedolizumab therapyClinical remissionMicroscopic colitisMucosal ulcerationSystemic immunosuppressionAdvanced malignanciesImportance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Abu-Sbeih H, Ali F, Luo W, Qiao W, Raju G, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2018, 6: 95. PMID: 30253811, PMCID: PMC6156850, DOI: 10.1186/s40425-018-0411-1.Peer-Reviewed Original ResearchConceptsEndoscopic featuresClinical outcomesHistologic featuresGrade 3Immune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisLogistic regressionActive histologic inflammationActive histological inflammationBackgroundImmune checkpoint inhibitorsExtensive colonic involvementMore frequent hospitalizationsMore recurrent symptomsHigh-risk featuresMultivariate logistic regressionSuch adverse eventsTime of onsetHistologic inflammationICPI treatmentCheckpoint inhibitorsColonic involvementEndoscopic inflammationHistological inflammationMucosal ulcerationRecurrent symptoms
2017
HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases
Matsye P, Zheng L, Si Y, Kim S, Luo W, Crossman D, Bratcher P, King P. HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases. Glia 2017, 65: 945-963. PMID: 28300326, PMCID: PMC7944581, DOI: 10.1002/glia.23137.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisNeurodegenerative diseasesIL-1βLateral sclerosisALS spinal cordMutant SOD1 micePossible therapeutic targetTranscription factor NF-κBLipopolysaccharide-induced IL-1βFactor NF-κBMolecular signaturesRole of HuRLuciferase reporter studiesActivated microgliaProinflammatory factorsSOD1 miceIL-6Inflammatory pathwaysMicroglial migrationImmune cellsSpinal cordChronic activationMicrogliaNF-κBTherapeutic target